Navigation Links
Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Date:5/22/2012

ntly reported rat and dog models confirm Unigene's prior preclinical studies.  These results support the Company's plans to commence Phase 1 clinical testing in obese subjects next year and indicate that, if these results can be reproduced in humans, UGP281 could potentially offer a new and very exciting treatment option in an area that clearly needs new and better treatments."

Nozer Mehta, PhD, Unigene's VP, Research and Development stated, "We are extremely pleased with our progress with UGP281 and continue to build an encouraging preclinical data set for our lead proprietary metabolic peptide."  Dr. Mehta continued, "UGP281's selective receptor-binding is anticipated to result in a cleaner and more attractive safety profile relative to several of the small molecule drug candidates or drug combinations currently, or previously, in development.  We continue to further differentiate UPG281 from other potentially competitive, peptide-based drugs and drug candidates and believe we will have the opportunity to optimally position UGP281 in this rapidly growing and significantly underserved market space."

Unigene is currently preparing for the submission of its Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and expects to be able to commence Phase 1 clinical testing of UGP281 in the first half of 2013.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering peptide drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets inclu
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
3. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
4. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
7. Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
8. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
9. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
10. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
11. Fujifilm Demonstrates the Latest Advancements of Synapse® PACS at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2011 Mylan Inc. (Nasdaq: MYL ) ... announced refinancing of its existing secured credit facility. The ... upsized from the originally planned $2.25 billion and comprises ... billion Term Loan A facility. The proceeds were used ...
... CLEVELAND and GAITHERSBURG, Md., Nov. 14, 2011 University ... School of Medicine and Lentigen Corporation announced today the ... LG631 gene therapy for the protection of hematopoietic stem ... with Temodar.   Approximately 17,000 Americans are ...
Cached Medicine Technology:Mylan Successfully Upsizes and Completes Refinancing of Credit Facility 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... by Vkool.com, this is a comprehensive guide that features ... deal with KP (keratosis pilaris). This guide ... 1: What Is Keratosis Pilaris? ,     Chapter 2: ... I Know If I Have KP? ,     Chapter ...
(Date:7/12/2014)... Fadhits.com, a well-known wedding dress manufacturer and retailer, has added ... to its product line. In addition, the company has launched ... bring more benefits for its loyal fans. All its ... to 72% off. , As a leader in the garment ... is a good place for ladies who want to purchase ...
(Date:7/12/2014)... 12, 2014 The Passenger Information System ... 2013 to $20,341.36 million by 2019, at an expected ... 2019. , The public transport infrastructure in North America ... available in almost every corner of the region. The ... of public transport service providers are driving the North ...
(Date:7/12/2014)... 12, 2014 The report, "Phthalic Anhydride ... Market by Application & Geography – Trends & Forecast ... analysis and forecasting of market volume and value. The ... derivatives separately. The market of phthalic anhydride is projected ... to $8,415.89 million by 2018, with a CAGR of ...
(Date:7/12/2014)... Dallas, TX (PRWEB) July 12, 2014 ... training market research report, ‘cognitive assessment and ... able to monitor, assess, train, or enhance ... several uses such as in dementia screening, ... concussion management, classroom learning, self assessment, brain ...
Breaking Medicine News(10 mins):Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5
... prompt consumers, food industry to consider ... benefits of natural sea salt, ... a dinner plate - yet that,s exactly what millions,of Americans unwittingly ... table salt, says Mark Zoske, co-founder of SaltWorks, Inc.,( http://www.seasalt.com ), ...
... -- China,Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN ... in the research, development, manufacture,and marketing of pharmaceutical, ... of China ("PRC"), today announced it will,conduct a ... April 2, 2008, to,discuss the Company,s financial results ...
... ... Enroll in Wellness Programs and Believe, that Yoga, Tai Chi and Other ... ... grow in,popularity, employees overwhelmingly see value in these healthy activities,but don,t stay committed to ...
... - Reduce pollution, save money., CHICAGO, March 31 ... "green" record by launching an innovative Shared,Bike Program on ... The Museum is a trendsetter for employee bicycle ... showers and bike parking,including a large, secure, indoor bike-parking ...
... a leading provider of laser vision correction services ... 76th LasikPlus(R) vision,center in Woodbridge, New Jersey. This ... year, and the second vision center,located in Northern ... Paramus in April 2006., Similar to other ...
... Inc. (Nasdaq: STRM ) today announced the financial ... 31, 2008., Revenues in the fourth quarter of ... with $3.8 million in the fourth quarter of fiscal,year ... $781 thousand, a,153% increase, compared with an Operating Profit ...
Cached Medicine News:Health News:SaltWorks, Inc. Advises Table Salt Alternatives 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 2Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 3Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 4Health News:Field Museum Launches Shared Bike Program for Employees 2Health News:LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey 2Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 2Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 3Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 4Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 5Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 6Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 7Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 8Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 9Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 10Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 11Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 12Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 13
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
Medicine Products: